Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Research and development revenue under collaboration agreement	$ 382	$ 3,549	$ 3,766	$ 7,023
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:InProcessResearchAndDevelopmentMember	us-gaap:InProcessResearchAndDevelopmentMember	us-gaap:InProcessResearchAndDevelopmentMember	us-gaap:InProcessResearchAndDevelopmentMember
Operating expenses:
Research and development	$ 15,488	$ 11,374	$ 29,831	$ 21,396
General and administrative	5,845	4,862	11,848	8,035
Total operating expenses	21,333	16,236	41,679	29,431
Loss from operations	(20,951)	(12,687)	(37,913)	(22,408)
Other income (expense)
Interest income	507	6	679	11
Other expense	(47)		(96)
Total other income, net	460	6	583	11
Net loss	(20,491)	$ (12,681)	(37,330)	$ (22,397)
Other comprehensive loss
Unrealized loss on marketable securities	(626)		(1,104)
Total comprehensive loss	$ (626)		$ (1,104)
Net loss per share:
Net loss per share attributable to common stockholders basic	$ (0.57)	$ (0.35)	$ (1.03)	$ (1.12)
Net loss per share attributable to common stockholders diluted	$ (0.57)	$ (0.35)	$ (1.03)	$ (1.12)
Weighted-average common stocks outstanding, basic	36,160,951	35,853,341	36,118,415	19,940,204
Weighted-average common stocks outstanding, diluted	36,160,951	35,853,341	36,118,415	19,940,204